% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rhle:163994,
      author       = {A. Rühle$^*$ and N. H. Nicolay$^*$},
      title        = {{D}e-escalation concepts for chemoradiotherapy of
                      {HPV}-positive oropharyngeal carcinomas: pros and
                      cons[{D}eeskalationsstrategien für die {R}adiochemotherapie
                      {HPV}-positiver {O}ropharynxkarzinome: {P}ro und {K}ontra].},
      journal      = {HNO},
      volume       = {69},
      number       = {4},
      issn         = {1433-0458},
      address      = {New York},
      publisher    = {Springer},
      reportid     = {DKFZ-2020-02194},
      pages        = {278-284},
      year         = {2021},
      note         = {2021 Apr;69(4):278-284},
      abstract     = {In contrast to alcohol- and nicotine-induced head and neck
                      tumors, human papillomavirus (HPV)-positive oropharyngeal
                      carcinoma rather affects younger patients, and the incidence
                      of this entity is continuously increasing. Due to the
                      significantly better prognosis of HPV-positive oropharyngeal
                      carcinoma, various treatment de-escalation strategies are
                      currently being investigated, with the aim of reducing
                      toxicity without affecting the good survival rates of these
                      patients.This study aims to evaluate the evidence for
                      treatment de-escalation in HPV-positive oropharyngeal
                      carcinoma.A literature search was performed and relevant
                      studies are critically discussed.De-escalation strategies
                      for HPV-associated oropharyngeal carcinoma using induction
                      chemotherapy or radiation dose reduction have demonstrated
                      good oncological results in phase II trials, with lower
                      toxicity rates compared to historical controls. However,
                      both of the first published phase III trials investigating
                      de-escalation of concomitant chemotherapy regimens
                      demonstrated inferior outcomes for the deescalated treatment
                      strategies without improvements in treatment-associated
                      toxicities. Additional phase-III trials investigating other
                      de-escalation strategies have not yet been
                      published.Treatment de-escalation should be performed
                      exclusively in prospective studies and can currently not be
                      recommended in clinical routine.},
      subtyp        = {Review Article},
      cin          = {FR01 / E055},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331 / I:(DE-He78)E055-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33048200},
      doi          = {10.1007/s00106-020-00955-5},
      url          = {https://inrepo02.dkfz.de/record/163994},
}